Here are the Endogenous C-type natriuretic peptide offsets the pathogenesis of steatohepatitis, hepatic fibrosis, and portal hypertension journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Endogenous c type natriuretic peptide normal range, endogenous c type natriuretic peptide offsets missouri, endogenous contamination, endogenous c type natriuretic peptide affinity chart, endogenous c type natriuretic peptide normal range levels, endogenous c type natriuretic peptide binding affinity.
Endogenous C-type natriuretic peptide offsets the pathogenesis of steatohepatitis, hepatic fibrosis, and portal hypertension
Metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis, and portal hypertension constitute an increasing public health problem due to the growing prevalence of obesity and diabetes. C-type natriuretic peptide (CNP) is an endogenous regulator of cardiovascular homeostasis, immune cell reactivity, and fibrotic disease. Thus, we investigated a role for CNP in the pathogenesis of MASLD. Wild-type (WT), global CNP (gbCNP−/−), and natriuretic peptide receptor-C (NPR-C−/−) knockout mice were fed a choline-deficient defined amino acid diet or administered CCl4. Liver damage was assessed by histological and biochemical analyses, with steatosis and portal vein size determined by ultrasound. Portal vein pressure and reactivity were measured in vivo and ex vivo, respectively. Pharmacological CNP delivery was used to evaluate prospective therapeutic benefit, and plasma CNP concentration was compared in controls and patients with cirrhosis. Circulating C NP concentration was lower in patients with cirrhosis compared with controls. gbCNP−/− mice were more susceptible, versus WT, to advanced steatohepatitis and hepatic fibrosis, characterized by increased immune cell infiltration, fibrosis, ballooning, plasma alanine aminotransferase concentration, and up-regulation of markers driving these processes. gbCNP−/− mice had increased portal vein diameter and pressure, underpinned by CNP insensitivity. NPR-C−/− animals recapitulated, comparatively, the exaggerated pathogenic phenotype in gbCNP−/− mice, whereas CNP reduced hepatic stellate cell proliferation via NPR-B-dependent inhibition of extracellular signal-related kinase 1/2. Administration of CNP reversed many aspects of disease severity. These data define a new intrinsic role for CNP in offsetting the pathogenesis of MASLD, hepatic fibrosis, and portal hypertension and the potential for targeting CNP signaling for treating these disorders. © The Author(s) 2024. Publi shed by Oxford University Press on behalf of National Academy of Sciences.
Authors : Perez-Ternero C.; Li W.; Aubdool A.A.; Goldin R.D.; Loy J.; Devalia K.; Alazawi W.; Hobbs A.J.
Source : National Academy of Sciences
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1093/pnasnexus/pgae579 |
| ISSN | 27526542 |
| Volume | 4 |
You can download the article here
If You have any problem, contact us here